42% lower risk of death supports priority review for AstraZeneca experimental drug
Key Facts
The U.S. Food and Drug Administration accepted AstraZeneca’s biologics license application for sonesitatug vedotin and granted it priority review for second-line and later treatment of certain advanced gastric, gastroesophageal junction and esophageal cancers. The company said the regulatory pathway is based on results from the CLARITY-Gastric01 trial, which showed a 42% lower risk of death with the drug than with investigator’s choice of treatment. Median overall survival was 10.6 months in the group that received the drug, compared with 6.4 months in the comparison group. The application covers locally advanced or metastatic tumors, with CLDN18.2 protein present in at least 25% of tumor cells at any staining intensity. The FDA is expected to take regulatory action during the second quarter of 2027, but priority review does not mean final approval.
Among patients who received treatment in the third line and beyond, AstraZeneca said the drug reduced the risk of death by 53% compared with investigator’s choice. Median overall survival in this group was 10 months with the drug versus 5 months in the comparison group. But progression-free survival, as assessed by a blinded independent review committee, did not reach statistical significance in the overall population; the p-value was 0.053193. This result highlights another aspect of the trial data alongside the improvement in overall survival, without changing the fact that the primary endpoint did not meet the statistical significance threshold. The company said treatment-related adverse events of Grade 3 or higher were reported in 36.4% of patients receiving the drug, compared with 44.8% in the comparator arm, and no new safety signals were reported.
The multicenter CLARITY-Gastric01 trial was conducted at 175 sites across 19 countries. Overall survival among patients in the third line and beyond, and progression-free survival in the overall population, were the trial’s primary endpoints. AstraZeneca published the study results on October 25, 2026, and said they were presented in a presidential session at the 2026 European Society for Medical Oncology Congress in Madrid. The U.S. application follows the results announcement and targets patients with advanced gastric, gastroesophageal junction or esophageal adenocarcinoma who meet the CLDN18.2 expression criteria. The company estimated that about 7,500 patients annually in the United States receive second-line and later treatment for advanced or metastatic gastric or gastroesophageal junction cancer, with CLDN18.2 positivity and HER2 negativity.
The drug has received orphan drug designation from the FDA and the European Commission for gastric and gastroesophageal junction cancers, and breakthrough therapy designation in China for second-line gastric cancer treatment. Under FDA guidelines, the priority review pathway targets action within 6 months, compared with a 10-month goal for standard review. The designation does not change the level of scientific or medical evidence required for approval. AstraZeneca is also studying the drug in the Phase 3 CLARITY-Gastric02 trial with capecitabine, with or without rilvegostomig, as first-line treatment for advanced or metastatic gastric, gastroesophageal junction and esophageal adenocarcinoma.
Development of treatments for these tumors comes amid a substantial global disease burden; the International Agency for Research on Cancer estimated that just under one million new cases of gastric cancer were recorded in 2024, and more than 640,000 people died from the disease that year. For the drug’s U.S. regulatory pathway, action on the application is expected in the second quarter of 2027. The outcome of that decision remains subject to the FDA’s assessment of the application and submitted data. In parallel, the company continues to evaluate the drug in the first-line CLARITY-Gastric02 trial. The study includes its use with capecitabine, with or without rilvegostomig, in patients with advanced or metastatic cancer.